Single ascending dose study evaluating safety, tolerability, and pharmacokinetics of VK3019 Potential to further expand Viking’s treatment options for weight loss SAN DIEGO, June 24, 2026 /PRNewswire/ — Viking Therapeutics, Inc. (“Viking”) (NASDAQ: VKTX), a clinical-stage…
Click here to view original post
Click Here to Publish/Feature Your Company or Product News with Biotech Networks
